Trial Profile
Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Mesothelin CAR T cell therapy Novartis/University of Pennsylvania (Primary)
- Indications Adenocarcinoma; Malignant-mesothelioma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
- Focus Adverse reactions
- 24 May 2018 New trial record